Literature DB >> 22514354

Modulation of the myxoma virus plaque phenotype by vaccinia virus protein F11.

Chad R Irwin1, David H Evans.   

Abstract

Vaccinia virus (VACV) produces large plaques consisting of a rapidly expanding ring of infected cells surrounding a lytic core, whereas myxoma virus (MYXV) produces small plaques that resemble a focus of transformed cells. This is odd, because bioinformatics suggests that MYXV carries homologs of nearly all of the genes regulating Orthopoxvirus attachment, entry, and exit. So why does MYXV produce foci? One notable difference is that MYXV-infected cells produce few of the actin microfilaments that promote VACV exit and spread. This suggested that although MYXV carries homologs of the required genes (A33R, A34R, A36R, and B5R), they are dysfunctional. To test this, we produced MYXV recombinants expressing these genes, but we could not enhance actin projectile formation even in cells expressing all four VACV proteins. Another notable difference between these viruses is that MYXV lacks a homolog of the F11L gene. F11 inhibits the RhoA-mDia signaling that maintains the integrity of the cortical actin layer. We constructed an MYXV strain encoding F11L and observed that, unlike wild-type MYXV, the recombinant virus disrupted actin stress fibers and produced plaques up to 4-fold larger than those of controls, and these plaques expanded ∼6-fold faster. These viruses also grew to higher titers in multistep growth conditions, produced higher levels of actin projectiles, and promoted infected cell movement, although neither process was to the extent of that observed in VACV-infected cells. Thus, one reason for why MYXV produces small plaques is that it cannot spread via actin filaments, although the reason for this deficiency remains obscure. A second reason is that leporipoxviruses lack vaccinia's capacity to disrupt cortical actin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22514354      PMCID: PMC3416311          DOI: 10.1128/JVI.06936-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  The release of vaccinia virus from infected cells requires RhoA-mDia modulation of cortical actin.

Authors:  Yoshiki Arakawa; João V Cordeiro; Sibylle Schleich; Timothy P Newsome; Michael Way
Journal:  Cell Host Microbe       Date:  2007-05-17       Impact factor: 21.023

2.  The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles.

Authors:  C M Sanderson; M Hollinshead; G L Smith
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

3.  Nck- and N-WASP-dependent actin-based motility is conserved in divergent vertebrate poxviruses.

Authors:  Mark P Dodding; Michael Way
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

4.  Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Authors:  David H Kirn; Yaohe Wang; Wenchung Liang; Christopher H Contag; Stephen H Thorne
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

5.  Vaccinia virus E2L null mutants exhibit a major reduction in extracellular virion formation and virus spread.

Authors:  Arban Domi; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

Review 6.  Vaccinia virus morphogenesis and dissemination.

Authors:  Kim L Roberts; Geoffrey L Smith
Journal:  Trends Microbiol       Date:  2008-09-12       Impact factor: 17.079

7.  Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions.

Authors:  George C Katsafanas; Bernard Moss
Journal:  Cell Host Microbe       Date:  2007-10-11       Impact factor: 21.023

8.  The vaccinia virus F11L gene product facilitates cell detachment and promotes migration.

Authors:  Ivonne Morales; Maria Alejandra Carbajal; Stefan Bohn; Daniela Holzer; Sayuri E M Kato; Frederico A B Greco; Nissin Moussatché; Jacomine Krijnse Locker
Journal:  Traffic       Date:  2008-06-28       Impact factor: 6.215

9.  Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly.

Authors:  Y-C James Lin; Jianhong Li; Chad R Irwin; Heather Jenkins; Luke DeLange; David H Evans
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.

Authors:  P S Satheshkumar; Bernard Moss
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

View more
  12 in total

1.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

2.  Genetic Variability of Myxoma Virus Genomes.

Authors:  Christoph Braun; Andrea Thürmer; Rolf Daniel; Anne-Kathrin Schultz; Ingo Bulla; Horst Schirrmeier; Dietmar Mayer; Andreas Neubert; Claus-Peter Czerny
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

3.  A whole-genome RNA interference screen for human cell factors affecting myxoma virus replication.

Authors:  Wondimagegnehu M Teferi; Kristopher Dodd; Rob Maranchuk; Nicole Favis; David H Evans
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 4.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

5.  Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Authors:  Chad R Irwin; Nicole A Favis; Kate C Agopsowicz; Mary M Hitt; David H Evans
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.

Authors:  Charlotte H Durkin; Flavia Leite; João V Cordeiro; Yutaka Handa; Yoshiki Arakawa; Ferran Valderrama; Michael Way
Journal:  Dev Cell       Date:  2017-05-08       Impact factor: 12.270

7.  Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility.

Authors:  Corina Beerli; Artur Yakimovich; Samuel Kilcher; Glennys V Reynoso; Gotthold Fläschner; Daniel J Müller; Heather D Hickman; Jason Mercer
Journal:  Nat Microbiol       Date:  2018-11-12       Impact factor: 17.745

Review 8.  Oncolytic Virotherapy with Myxoma Virus.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Clin Med       Date:  2020-01-08       Impact factor: 4.241

9.  TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry.

Authors:  Ismar R Haga; Tali Pechenick Jowers; Samantha J Griffiths; Juergen Haas; Philippa M Beard
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

10.  Ectromelia Virus Affects Mitochondrial Network Morphology, Distribution, and Physiology in Murine Fibroblasts and Macrophage Cell Line.

Authors:  Karolina P Gregorczyk; Zbigniew Wyżewski; Joanna Szczepanowska; Felix N Toka; Matylda B Mielcarska; Magdalena Bossowska-Nowicka; Małgorzata Gieryńska; Anna Boratyńska-Jasińska; Justyna Struzik; Marek G Niemiałtowski; Lidia Szulc-Dąbrowska
Journal:  Viruses       Date:  2018-05-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.